Cardiovascular risk in vasculitis

Best Pract Res Clin Rheumatol. 2023 Mar;37(1):101831. doi: 10.1016/j.berh.2023.101831. Epub 2023 Jun 9.

Abstract

The present review summarizes the burden, risk factors, biomarkers of and therapeutic consideration for cardiovascular disease in systemic vasculitis. Ischemic heart disease (IHD) and stroke are intrinsic features of Kawasaki disease, Takayasu arteritis, Giant Cell Arteritis (GCA), and Behcet's disease. The risk of IHD and stroke is increased in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and cryoglobulinemic vasculitis. Behcet's disease could present with venous thromboembolism. The risk of venous thromboembolism is increased in AAV, polyarteritis nodosa, and GCA. The risk of cardiovascular events is greatest at or immediately after the diagnosis of AAV or GCA, therefore, controlling vasculitis disease activity is of utmost importance. Traditional as well as disease-related risk factors drive the heightened cardiovascular risk in vasculitis. Aspirin or statins reduce the risk of IHD or stroke in GCA or the risk of IHD in Kawasaki Disease. Venous thromboembolism in Behcet's disease should be treated with immunosuppressive therapy rather than with anticoagulation.

Keywords: Anti-neutrophil cytoplasmic antibody-associated vasculitis; Behcet disease; Cardiovascular risk; Giant cell arteritis; Systemic vasculitis; Takayasu arteritis.

Publication types

  • Review

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis*
  • Behcet Syndrome* / complications
  • Behcet Syndrome* / epidemiology
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Giant Cell Arteritis* / complications
  • Giant Cell Arteritis* / drug therapy
  • Giant Cell Arteritis* / epidemiology
  • Heart Disease Risk Factors
  • Humans
  • Risk Factors
  • Stroke* / epidemiology
  • Stroke* / etiology
  • Venous Thromboembolism* / epidemiology
  • Venous Thromboembolism* / etiology